Vertex Appoints Nancy Thornberry to its Board of Directors
December 05 2023 - 4:01PM
Business Wire
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
announced that Nancy Thornberry has been appointed to its Board of
Directors as an independent director. Ms. Thornberry has more than
35 years of experience in the pharmaceutical and biotech
industries, spanning drug discovery, development and
commercialization. She founded and served as Chief Executive
Officer of Kallyope until 2021 and remains on its Board of
Directors and is Chair of Research & Development. Prior to
joining Kallyope, Ms. Thornberry spent more than 30 years at Merck
& Co., Inc., most recently as Senior Vice President and Global
Franchise Head, Diabetes and Endocrinology, with responsibility for
discovery and clinical research in diabetes, obesity and women’s
health. Among her many notable scientific accomplishments, Ms.
Thornberry initiated and led Merck’s dipeptidyl peptidase 4 (DPP-4)
project, which resulted in the discovery and commercialization of
JANUVIA® for the treatment of type 2 diabetes, the best-selling
oral product franchise in Merck's history. She also identified the
first caspase, interleukin-1β converting enzyme
(ICE/caspase-1).
“Scientific innovation is a core Vertex value and Nancy brings
to our Board deep scientific expertise and a remarkable track
record of discovering and developing groundbreaking medicines. Her
industry experience, scientific acumen and strategic thinking will
add great value to our company as we continue to expand and
progress our broad and deep pipeline of novel and innovative
therapies for serious diseases,” said Jeffrey Leiden, M.D., Ph.D.,
Executive Chairman of Vertex.
“Vertex has delivered a series of scientific breakthroughs that
have resulted in life-changing medicines for patients with serious
diseases such as cystic fibrosis and sickle cell disease. And
today, they are on the cusp of transforming the treatment of
multiple additional serious diseases,” said Nancy Thornberry. “The
Vertex strategy and commitment to serial innovation are delivering
for patients, and I am honored to join this Board to help Vertex
continue to advance its exciting pipeline.”
In addition to her role at Kallyope, Ms. Thornberry serves on
the Board of Directors of Schr�dinger, Inc., Denali Therapeutics
Inc. and the New York Genome Center, and as an Advisor to GV
(Google Ventures). Ms. Thornberry holds a Bachelor of Science in
chemistry and biology from Muhlenberg College.
About Vertex
Vertex is a global biotechnology company that invests in
scientific innovation to create transformative medicines for people
with serious diseases. The company has approved medicines that
treat the underlying causes of multiple chronic, life-shortening
genetic diseases — cystic fibrosis, sickle cell disease and
transfusion-dependent beta thalassemia — and continues to advance
clinical and research programs in these diseases. Vertex also has a
robust clinical pipeline of investigational therapies across a
range of modalities in other serious diseases where it has deep
insight into causal human biology, including APOL1-mediated kidney
disease, acute and neuropathic pain, type 1 diabetes and alpha-1
antitrypsin deficiency.
Vertex was founded in 1989 and has its global headquarters in
Boston, with international headquarters in London. Additionally,
the company has research and development sites and commercial
offices in North America, Europe, Australia and Latin America.
Vertex is consistently recognized as one of the industry's top
places to work, including 14 consecutive years on Science
magazine's Top Employers list and one of Fortune’s 100 Best
Companies to Work For. For company updates and to learn more about
Vertex's history of innovation, visit www.vrtx.com or follow us on
LinkedIn, Facebook, Instagram, YouTube and Twitter/X.
(VRTX-GEN)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231204739862/en/
Vertex Pharmaceuticals Incorporated Investors:
InvestorInfo@vrtx.com Susie Lisa, CFA: +1 617-341-6108 or Manisha
Pai: +1 617-961-1899 or Miroslava Minkova: +1 617-341-6135
Media: mediainfo@vrtx.com or U.S.: +1 617-341-6992 or
Heather Nichols: +1 617-839-3607
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Jul 2023 to Jul 2024